

















































Nesfatin-1 is processed by cleavage of a precursor, 
NEFA/nucleobindin2 (NUCB2), and is distributed in the 
central nervous system (CNS) implicated in the 


















































ventricular nucleus (PVN), arcuate nucleus (ARC), 
lateral hypothalamic area and supraoptic nucleus (SON) 
[1]. Double-labeling immunohistochemistry in these 
areas has revealed that nesfatin-1 is colocalized with 
feeding-related factors such as corticotropin-releasing 









































and  colocalized  with  stress‐related  substances,  corticotropin‐releasing  hormone  (CRH),  oxytocin,  proopiomelanocortin,
noradrenaline (NA) and 5‐hydroxytryptamine (5‐HT). Intracerebroventricular (icv) administration of nesfatin‐1 produces








concentration  in  the  CRH‐immunoreactive  neurons  isolated  from  PVN.  Icv  nesfatin‐1  increased  plasma  ACTH  and
corticosterone levels. These results indicate that the central nesfatin‐1 system is stimulated by stress and activates CRH, NA
and 5‐HT neurons and hypothalamic‐pituitary‐adrenal axis, evoking both central and peripheral stress responses.  
  www.impactaging.com AGING, November 2010, Vol 2 N 11
   
www.impactaging.com                   775                                   AGING, November 2   010, Vol.2 No.11(POMC) and cocaine-amphetamine-regulated transcript 
(CART) [2-4]. Central administration of α-MSH 
increases NUCB2 mRNA in the hypothalamus. 
Anorectic effect of icv nesfatin-1 is mediated by the PVN 
oxytocin [5] to NTS POMC circuit [6]. Nesfatin-1 and 
oxytocin both suppresses food intake in Zucker-fatty rats 
with mutated leptin receptor, and leptin-induced satiety is 
unaltered by immunoneutralizing nesfatin-1 IgG [1,6]. 
These results suggest that nesfatin-1 induces anorexia in 
a leptin-independent and melanocortin-dependent manner 
[1,6]. It has also been reported that the anorectic action of 
nesfatin-1 involves the CRH pathway [7]. The CRH and 
melanocortin [10] pathways are implicated in stress.  
 
Several studies have suggested a possible link of 
nesfatin-1 to stress responses. Nesfatin-1 is distributed in 
the stress-related areas, including the nucleus of solitary 
tract (NTS), locus coeruleus (LC) and raphe pallidus 
nucleus (RPa) [3] as well as PVN. Furthermore, nesfatin-
1 is colocalized with CRH in the PVN and with 
noradrenaline (NA) and 5-hydroxytryptamine (5-HT) in 
the brain stem [3]. CRH in the PVN drives release of 
ACTH and corticosterone, evoking the hypothalamic-
pituitary-adrenal (HPA) axis characteristically implicated 
in the stress responses, and NA and 5-HT modulate the 
HPA axis. Peripheral injection of 5-HT2C agonist 
increases NUCB2 mRNA in the hypothalamus [8]. 
Central administration of nesfatin-1 produces anorexi-
genic and fear-related behaviors in several animal models 
[9]. Nesfatin-1 activates melanocortin pathway [1,6] 
implicated in stress responses [10]. Based on these 
























as a stress mediator. Nesfatin-1 is also localized in the 
peripheral tissues including stomach [11,12], pancreas 
[13,14] and adipose tissue [15], though its function 
remains largely unknown.  
 
This study aimed to clarify whether the central nesfatin-
1 system and/or the plasma nesfatin-1 level is activated 
by restraint stress, to specify the central areas and 
neuron species targeted by stress and icv nesfatin-1, and 
to examine whether icv nesfatin-1 stimulates HPA axis 
in rats. c-Fos protein expression was examined to detect 
neuronal activation. Direct effects of nesfatin-1 on 
specified neurons were determined by measurement of 
cytosolic Ca
2+ concentration ([Ca
2+]i) in isolated 
neurons combined with immuno-cytochemistry. We 
here show that the central nesfatin-1 is stimulated by 
stressor and that icv nesfatin-1 activates CRH, NA and 




Nesfatin-1 was colocalized with TH in the NTS and 
LC 
 
Double fluorescence immunohistochemistry in the LC 
showed that immunoreactivity for TH (Figure 1A) and 
that for nesfatin-1 (Figure 1B) overlapped extensively in 
neurons in the LC (Figure 1C), demonstrating 
colocalization of two molecules in the LC neurons. 
Similarly, immunoreactivities for TH (Figure 1D) and 
nesfatin-1 (Figure 1E) overlapped in neurons in the NTS 


























LC.  (D‐F)  Neurons  IR  to  nesfatin‐1  (green)  (D)  and  TH  (red)  (E),  and  their  merged  image  (F)  in  the  NTS.
Colocalization of nesfatin‐1 with TH is seen by yellow color in (C) and (F). Scale bar, 100 μm. 4V, forth ventricle. 
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1 neurons in the hypothalamus and brain stem but 
failed to alter plasma nesfatin-1 concentrations 
 
Exposure of rats to restraint stress for 60 min, as 
compared to control groups without stress, induced c-Fos 
expression in the areas of the hypothalamus and brain 
stem where nesfatin-1 is localized. In the PVN, the 
number of c-Fos immunoreactive (IR) neurons in stress 
groups (180.3 ± 13.5 neurons/section, n = 12 slices) were 
significantly (P < 0.01) greater than those in control 
groups (5.8 ± 1.0 neurons/section, n = 13) (Figures 2A 
and G). In these c-Fos-expressing neurons, 47.1 ± 3.2% 










































tin-1-IR neurons expressed c-Fos in stress groups, while 
only 1.5 ± 0.4% in control groups (Figures 2A and F). 
Stress also induced significant c-Fos expression in 
nesfatin-1 neurons in the SON, ARC, NTS and LC 
(Figures 2B-E and F). c-Fos expression was significantly 
increased (9.3 ± 2.0, n = 17, in stress group vs. 0.2 ± 0.1, 
n = 22, in control group, P < 0.01) in the DR. The 
nesfatin-1 level in the blood from jugular vein in rats 
after exposure to restraint stress for 15 min (2.5 ± 0.4 
ng/ml, n = 3) was not different from that in control rats 
(2.5 ± 0.2 ng/ml, n = 3), and the nesfatin-1 level in the 
blood from portal vein was not different between stress 
(3.1 ± 0.5 ng/ml, n = 3) and control groups (3.0 ± 0.2 












































levels  after  restraint  stress.  (A‐E) Double‐immunohistochemical staining of c‐Fos (black) and nesfatin‐1
(brown) in the PVN (A), SON (B), ARC (C), NTS (D) and LC (E) in control conditions (left panels) and after restraint

















































Icv administration of nesfatin-1 induced c-Fos 
expression in stress-related nuclei  
 
We next examined which of the brain areas could be 
activated by icv nesfatin-1. Injection of nesfatin-1 into 3v 
(0.5 nmol/5 μl) significantly increased the number of 
neurons that expressed c-Fos in the PVN (nesf-1; 62.3 ± 
4.2, n = 22 slices, vs. saline; 27.2 ± 3.8, n = 20 slices; 
Figure 3-A,H), SON (nesf-1; 10.7 ± 3.0, n = 31, vs. 
saline; 3.2 ± 1.0, n = 27; Figure 3-B,H), NTS (nesf-1; 
22.1 ± 3.5, n = 23, vs. saline; 12.2 ± 1.7, n = 20; Figure 3-












































n = 15; Figure 3-E,H), dorsal raphe nucleus (DR) (nesf-1; 
152.2 ± 25.2, n = 29, vs. saline; 23.0 ± 3.7, n = 25; Figure 
3-F,H) and median raphe nucleus (MR) (nesf-1; 12.5 ± 
4.9, n = 18, vs. saline; 0.1 ± 0.1, n = 14; Figure 3-G,H) . 
Nesfatin-1 failed to induce c-Fos in the ARC (Figure 3-
C,H). 
 
Icv nesfatin-1 induced c-Fos expression in neurons 
containing stress-related neurohormones 
 
We intended to identify the target neurons for central 
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CRH neurons in the PVN (Figure 4A): the incidence of 
c-Fos expression in CRH neurons was significantly (P < 
0.05) higher after nesfatin-1 treatment (28.3 ± 7.7%, n = 
12 slices) compared to saline treatment (3.9 ± 1.0%, n = 
9) (Figure 4E). Vice versa, a large fraction of the c-Fos-
expressing neurons after icv nesfatin-1 (44.2 ± 6.7%, n = 
12) contained CRH. These data indicated that CRH 
neuron was a major target of icv nesfatin-1 in the PVN. 
In the DR, icv nesfatin-1 increased the incidence of c-Fos 
expression in tryptophan hydroxylase (TPH)-IR neurons 
(nesf-1; 15.1 ± 3.3%, n = 29 vs. saline; 5.8 ± 2.2%, n = 
27, P < 0.05) (Figures 4B and E). Vice versa, 15.3 ± 
2.3% of the neurons that expressed c-Fos after icv 









































that 5-HT neuron was a target of icv nesfatin-1 in the DR. 
In the NTS, icv nesfatin-1 increased the incidence of c-
Fos expression in TH-IR neurons (nesf-1; 15.4 ± 4.9%, n 
= 24, vs. saline; 1.6 ± 0.5%, n = 21, P < 0.05) (Figures 
4D and E). Vice versa, 23.9 ± 4.2% (n = 22) of the 
neurons that expressed c-Fos after icv nesfatin-1 
contained TH. These data indicated that noradrenalin 
neuron was a substantial target of icv nesfatin-1 in the 
NTS. In the LC, nesfatin-1 induced a marked c-Fos 
expression in TH-IR neurons (Figure 4E). However, it 
was difficult to count c-Fos-expressing TH-IR neurons 
since neurons extensively overlapped to each other. In 
addition, icv nesfatin-1 also increased the incidence of c-
Fos expression in oxytocin neurons in the PVN (data not 
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2+]i in single CRH neurons in 
the PVN 
 
The results that icv nesfatin-1 induced c-Fos in CRH 
neurons raised a question whether nesfatin-1 could 
directly interact with this neuron. Administration of 10
-10 
M nesfatin-1 increased [Ca
2+]i in a single neuron isolated 
from the PVN (Figure 5A, left), and the neuron was 
subsequently shown to be immunoreactive to CRH 
(Figure 5A, right). Nesfatin-1 at 10
-10 M increased [Ca
2+]i 
in 4 out of 16 PVN CRH-IR neurons (25%). The results 
revealed that nesfatin-1 directly interacts with and 
increases [Ca

























The effect of central nesfatin-1 on plasma ACTH and 
corticosterone levels 
 
The result that nesfatin-1 activated CRH neurons 
suggested a possibility that this action is linked to the 
HPA axis. Icv nesfatin-1 significantly increased the 
plasma ACTH levels at 10 min after administration, 
compared to icv saline (247.1 ± 46.8 pg/ml (n = 15) with 
nesfatin-1 vs. 143.4 ± 14.7 pg/ml (n = 15) with saline, p < 
0.05). Icv nesfatin-1 also significantly increased the 
plasma corticosterone levels at 15 min after 
administration, compared with control (228.0 ± 54.9 
ng/ml (n = 11) with nesfatin-1 vs. 100.4 ± 20.6 ng/ml (n 
= 11) with saline, p < 0.05). The elevated levels of 
ACTH and corticosterone returned to the basal levels at 
30 and 60 min after administration, respectively (data not 
shown). These data demonstrate that icv nesfatin-1 
























The present study has demonstrated that the central 
nesfatin-1 system but not the plasma nesfatin-1 level is 
activated by restraint stress and that icv nesfatin-1 
activates CRH, noradrenaline and 5-HT neurons and 
increases plasma ACTH and glucocorticoid levels.  
 
In this study, restraint stress induced abundant c-Fos 
expressions in nesfatin-1 neurons in the stress-related 
brain areas, PVN, SON, NTS and LC, confirming the 
recent report by Goebel et al. [17]. More importantly, we 
have found for the first time that centrally administered 
nesfatin-1 induced significant c-Fos expression in PVN, 
SON, NTS, LC, DR and MR, including more specifically 
the CRH neurons of PVN, the NA neurons of NTS and 
LC, and the 5-HT neurons of DR. In addition, we have 
first demonstrated that nesfatin-1 directly interacted with 
and increased [Ca
2+]i in the CRH neurons isolated from 
PVN, and that centrally administered nesfatin-1 by itself, 
with no added stress, increased plasma ACTH and 
corticosterone levels. These results collectively 
demonstrate that the nesfatin-1 neuronal system in the 
hypothalamus and brain stem respond to stressor and 
evokes central stress responses leading to activation of 
the HPA axis. This mechanism may underlie the nesfatin-
1-induced stress-related behaviors [18].  
 
In the present study, we confirmed previous report that 
nesfatin-1 is colocalized with NA in the NTS [3] and 
added that nesfatin-1 is also colocalized with NA in the 
LC, the area of the largest source of NA neurons. We 
Figure  5.  The  effect  of  nesfatin‐1  on  [Ca
2+]i in  CRH
neurons  in  the  PVN. Administration of 10
‐10 M nesfatin‐1
increased  [Ca
2+]i in  a  single  neuron  isolated  from  PVN  (left
panel)  that  was  subsequently  shown  to  be  IR  to  CRH  (light





min  (A)  and  corticosterone  levels  at  15  min  (B)  after  icv
administration  of  nesfatin‐1  (0.5  nmol/5  μl)  were  increased
compared with saline administration. *p < 0.05 vs. saline. 
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nesfatin-1 neurons in the PVN, SON, LC, and NTS are 
activated by stress and added that those in the ARC are 
also activated by stress and that plasma nesfatin-1 
concentrations are altered neither by restraint stress nor 
by a stronger stress of water immersion-restraint (data not 
shown). These results suggest that the central but not 
peripheral nesfatin-1 is involved in stress responses. 
  
We showed that icv injection of nesfatin-1 induces c-Fos 
expression in CRH, NA and 5-HT neurons in the PVN, 
NTS and DR, respectively. In particular, a large fraction 
(28.3%) of CRH neurons expresses c-Fos in the PVN 
after icv nesfatin-1. Furthermore, nesfatin-1 directly 
interacts with and increases [Ca
2+]i in a substantial 
fraction (25%) of CRH neurons isolated from the PVN, 
in accord with previous report that nesfatin-1 changes 
electrical activities of CRH neurons [19]. Thus, nesfatin-
1 activates CRH neurons both in vivo and ex vivo. These 
results demonstrate that nesfatin-1 targets the PVN CRH 
neurons. 
 
In the present study we have demonstrated that icv 
nesfatin-1 increases plasma ACTH and corticosterone 
concentrations confirming the previous report [20]. After 
icv administration of nesfatin-1, plasma ACTH and 
corticosterone levels increased at 10 and 15 min and 
returned toward basal levels at 30 and 60 min, 
respectively. This time course of plasma ACTH levels 
fits with the reports that plasma ACTH concentrations 
increase maximally at 5-15 min after administration of 
several stress-related neuro-peptides [21-23] and under 
restraint stress conditions [24]. On the other hand, our 
data of the time course of plasma corticosterone levels 
appear somewhat shorter-lasting than those previously 
reported in which the plasma corticosterone reaches and 
keeps maximum levels during 30-120 min, and then 
declines to the basal levels [23,25]. Our data of relatively 
shorter-lasting increase of plasma corticosterone by icv 
nesfatin-1 may suggest that the central nesfatin-1 is 
implicated in the initiation or the early phase of stress 
responses.  
 
It has been shown that nesfatin-1 is localized not only in 
the central nervous system but in the peripheral tissues 
including stomach [11,12], pancreas [13,14], and adipose 
tissue [15]. The present study indicated that stress 
induced c-Fos in the nesfatin-1 neurons without altering 
plasma nesfatin-1 levels. The results suggest that stress 
involves the central but not circulating nesfatin-1. The 
precise neural mechanism by which nesfatin-1 neurons 
mediate stress responses remain to be elucidated. 
However, the nesfatin-1 neurons in the stress-activated 
nuclei such as NTS, LC and SON may project to the 
PVN CRH neurons. Alternatively, stress-activated 
nesfatin-1 neurons in the PVN may activate CRH 
neurons via a paracrine and/or ultrashort feedback 
regulation, which is supported by that nesfatin-1 is 
localized in secretory vehicles in PVN neurons [6].  
 
We found that central nesfatin-1 also activates NA 
neurons in the NTS and LC and 5-HT neurons in the DR 
of the brain stem. It has been documented that these NA 
and 5-HT neurons project to PVN [26-28] including 
CRH neurons [29-31], being relayed to activation of 
HPA axis [32-35]. Our data together with these 
documents suggest that the nesfatin-1-activated NA and 
5-HT neurons project to and stimulate PVN CRH 
neurons and that this pathway partly contributes to the 
nesfatin-1 activation of HPA axis. 
 
We found that icv nesfatin-1 induces c-Fos expression in 
5-HT neurons. Vice versa, peripheral injection of a 5-HT 
receptor agonist reportedly increases NUCB2 mRNA 
expressions in the hypothalamus [8]. These findings 
suggest a bidirectional interaction between 5-HT and 
nesfatin-1 neurons.  
 
In summary, this study presents evidence to support that 
stressor-responsive nesfatin-1 neurons in the 
hypothalamus and brain stem activate the CRH, NA and 
5-HT neurons and evoke HPA axis, thus inducing stress 
responses. Central nesfatin-1 system could provide a 
potential therapeutic target for treating stress-related 




Animals. Male Sprague Dawley rats aged 7-8 weeks 
were housed in individual cages and maintained under a 
controlled environment (12h/12h dark/light cycle, lights 
on at 07:30) and allowed free access to conventional food 
(CE-2; Clea, Osaka, Japan) and water ad libitum. All 
procedures were performed in accordance with 
institutional guidelines for Animal Care at Jichi Medical 
University. 
 
Restraint stress. Rats were wrapped in a wire mesh and 
kept in their cages for 15 or 60 min. Control rats were left 
in their cages without any treatment. At the termination 
of the stress period, animals were released from a wire 
mesh. The stress was given in day time (10:00-14:00h). 
 
Intracerebroventricular cannulation. Rats were anesthe-
tized by injection of Avertin (Tribromoethanol, 200 
mg/kg, ip) and placed in a stereotaxic frame (DAVIO 
Kopf Instruments, Tujunga, CA), and a stainless steel 
guide cannula (26 gauge) was inserted into the brain with 
the tip in the third ventricle (3v); 2.5 mm posterior from 
the bregma and 8 mm below the skull). Rats were 
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and were handled daily to minimize non specific stress 
responses. Substances were administered into 3v via a 
stainless steel injector (30 gauge) through the guide 
cannula. Rats received an administration of 0.5 nmol 
nesfatin-1 in 5 μl of 0.9 % NaCl into 3v. Experiments 
were carried out during the light phase (for immuno-
histochemical study at 10:00-14:00h, and for blood 
collection at 10:00-11:00h). Hypothalamic sections were 
histologically examined at the end of the study, and the 
placement of the cannula was verified. The rats in which 
cannulae were outside 3v were excluded from the data 
analysis.  
 
Tissue preparation for immunohistochemistry. At 2 h 
after 60 min restraint stress and at 2 h after icv 
administration of nesfatin-1, rats were deeply 
anesthetized with urethane (1 g/kg, ip) and perfused with 
saline containing heparin (20 U/ml) and then 4% 
paraformaldehyde in 0.1 M phosphate buffer. The brains 
were immediately removed, postfixed in the same 
fixative overnight at 4°C, and then immersed in PBS 
containing 30% sucrose for at least 2 days at 4°C. The 
brains were frozen on dry ice and kept at -80°C until 
sectioning. Frozen frontal sections (40 μm) were 
prepared with a freezing microtome and collected at 240 
μm intervals. In immunohistochemical studies, each 
quantitative analysis was performed in 9 to 32 sections 
collected from 3 animals. 
 
Double-labeling immunohistochemistry for nesfatin-1 
and TH. Fixed brain sections were prepared during 
10:00-14:00h as described above. Secitons were rinsed in 
PBS, and then incubated in 0.3% TritonX containing 
PBS (PBST) for 30 min and then blocked for 30 min in 
2% BSA-containing PBST. Finally, sections were 
incubated with rabbi anti-nesfatin-1 antibody (1:1000) 
(Oh-I et al. 2006) and mouse monoclonal anti-tyrosine 
hydroxylase clone TH2 antibody (Sigma Aldrich, MO 
;1:4000) overnight at 4°C. Then the sections were rinsed 
and incubated with secondary antibodies, Alexa 488 goat 
anti-rabbit IgG (Invitrogen Co., CA ; 1:500) and Alexa 
594 goat anti-mouse IgG (Invitrogen Co., CA ; 1:500) for 
40 min. Slices were then rinsed, mounted on slides, and 
coverslipped with fluorescent mounting medium 
(DakoCytomatin, Carpinteria, CA). Fluorescence images 
were acquired with a BX50 microscope and a DP50 
digital camera (Olympus, Tokyo, Japan). Using 
Photoshop (Adobe, San Jose, CA), brightness and 
contrast were adjusted, and fluorescence photographs 
were combined to visualize double-labeled cells by the 
screen blending mode. 
c-Fos immunohistochemistry. Fixed brain tissues were 
prepared as described above. Sections were rinsed in 
PBS, and then incubated in PBS containing 0.3% H2O2 
for 30 min to quench endogenous peroxidase. After the 
rinse, sections were incubated in PBST for 30 min and 
then blocked for 30 min in 2% BSA-containing PBST. 
Finally, sections were incubated with rabbit anti c-Fos 
antibody (Ab-5; Calbiochem, CA; 1:40,000) overnight at 
4°C. Then the sections were rinsed and incubated with 
biotinylated goat anti-rabbit IgG (Vector Laboratories, 
CA; 1:500) for 30 min and then with ABC reagent 
(Vector Laboratories, CA; ABC KIT) for 30 min. After 
the rinse in PBS and 0.05 M Tris-HCl buffer (pH7.4), 
color was developed with a nickel-diaminobenzidine 
(DAB) solution (0.2 g/liter DAB and 0.015 % H2O2 in 
0.05 M Tris-HCl buffer (pH7.4)) for 5 min. Slices were 
mounted on slides and coverslipped with Entellan new 
(Merck, Darmstadt, Germany). 
 
Double-labeling immunohistochemistry for c-Fos and 
nesfatin-1, CRH, NA or 5-HT. Double-labeling immuno-
histochemistory for c-Fos together with nesfatin-1, CRH, 
NA or 5-HT was performed by the procedures stated 
above and according to Kohno et al. [2].  Rabbit anti 
nesfatin-1 antibody (1:5000) [1], rabbit anti CRH 
antibody (BACHEM, CA, 1:5000), mouse monoclonal 
anti-TH2 antibody (Sigma Aldrich, 1:4000) or mouse 
monoclonal anti-tryptophan hydroxylase (Ab-1) antibody 




2+]i in single PVN neurons. [Ca
2+]i 
was measured by radiometric fura-2 microfluorometry in 
combination with digital imaging as previously reported 
[6]. Briefly, following incubation with 2 μmol/l 
fura2/AM (Dojin Chemical, Kumamoto, Japan) for 1 h at 
18C, the cells were mounted in a chamber and superfused 
with HKRB at 1 ml/min at 33°C. Fluorescence images 
due to excitation at 340 and 380 nm were detected every 
8.0 s with an intensified charge-coupled device (ICCD) 
camera, and the ratio (F340/F380) image was produced 
by an Argus-50 system (Hamamatsu Photonics, 
Hamamatsu, Japan). When [Ca
2+]i increased within 5 min 
after addition of nesfatin-1 with the ratio changes greater 
than 0.3, they were considered responses. Data were 
taken from the cells that were identified as neurons by the 
criteria reported previously [16].  
 
Effect of stress on plasma nesfatin-1 levels. After 
restraint stress for 15 min given in day-time (10:00-
14:00h), rats were anaesthetized by injection of urethane 
(1 g/kg, ip) and then blood were collected from jugular 
vein or portal vein. After addition of 1/10 amounts of 1 N 
HCl to the plasma, plasma was stored at -80°C until the 
measurement of nesfatin-1. The plasma nesfatin-1 
concentrations were measured with a RIA kit (Phoenix 
Parmaceuticals, Inc., CA).  
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Effect of 3v nesfatin-1 administration on plasma ACTH 
and corticosterone levels. At 10 min (for ACTH) or 15 
min (for corticosterone) after icv administration of 
nesfatin-1, rats were decapitated and blood was collected 
into tubes containing EDTA and aprotinin. Plasma was 
separated from blood and stored at -80°C until the 
measurement of ACTH or corticosterone. The plasma 
ACTH concentrations were measured with a RIA kit 
(Mitsubishi Chemical Medience Co., Tokyo, Japan) and 
plasma corticosterone concentrations with an ELISA kit 
(Assaypro, MO). These studies were performed during 
day-time (10:00-11:00h). 
 
Statistics. All data were presented as the means ± SEM (n 
= number of animals or slices). Statistical analysis was 
carried out using Student’s t test for two-group 
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